{
    "nct_id": "NCT05551858",
    "official_title": "A Phase 1/2 Trial to Test the Safety of a CCK Receptor Antagonist, Proglumide, in Management of Chronic Pancreatitis Symptoms and Pain for 12 to 24 Months",
    "inclusion_criteria": "* Males or females age 18 to 75 years of age\n* Clinical symptoms of chronic pancreatitis\n* Plus confirmation of chronic pancreatitis with imaging (Cambridge classification), EUS, biopsy, or fecal elastase <200Âµg/g, or abnormal 72 hr fecal fat and radiographic evidence of CP.\n* Pain not adequately controlled with medications\n* Pain of at least 5 on a numeric pain scale of 0-10\n* Stable doses of anti-diabetic medication for at least 90 days prior to screening.\n* Women of childbearing potential unless surgically sterile or using adequate contraception (either IUD, oral or deport contraceptive, or barrier plus spermicide).\n* Both males and females must be willing and able to continue contraception to prevent pregnancy for 3 months after the completion of the study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Currently abusing alcohol (more than three drinks in a day or more than seven drinks per week) or nonprescription drugs\n* Pregnant or lactating, or unwilling to prevent pregnancy\n* Renal insufficiency; CKD; GFR<60\n* Unable to sign consent or maintain a diary\n* Liver enzymes > 2x ULN, Hgb <8.5, Creat>2; HgbA1c>8\n* Type 1 Diabetes\n* Subjects with confirmed cirrhosis\n* Evidence of active gallbladder disease or gallbladder dyskinesia",
    "miscellaneous_criteria": "Subjects are eligible with a history of chronic pancreatitis as defined by the Cambridge radiographic classification with abnormal pancreatic side branches but without main pancreatic duct obstructing calcifications."
}